Outpatient surgical procedures are now more common than inpatient procedures, given the development of less invasive techniques, the drive for healthcare efficiency, and improvements in anesthesia and pain management.\textsuperscript{1–4} Postoperative pain management after outpatient procedures often includes low-potency or low-dose opioids.\textsuperscript{5} Codeine use is widespread in this setting and codeine remains the most commonly prescribed opioid in many countries, including Canada.\textsuperscript{6–9} However, its efficacy is variable, its potency is low and its use is associated with risks of severe adverse effects and misuse.\textsuperscript{10} Amid the ongoing opioid crisis, management of pain and potential opioid misuse is important across all medical and dental specialties.\textsuperscript{11}

Nonsteroidal anti-inflammatory drugs (NSAIDs) are an alternative to low-potency opioids. The potency, effects and toxicity of NSAIDs depend on the degree to which they inhibit cyclooxygenase 1 and 2 activity. Their main adverse effects are gastrointestinal bleeding, renal impairment and myocardial infarction with long-term use.\textsuperscript{12–15} Postoperative pain can be effectively managed with NSAIDs, and NSAIDs have been shown to reduce opioid consumption in postoperative patients.\textsuperscript{16} Given how commonly these medications are used, and the uncertainty in their comparative efficacy and safety, we sought to compare pain and safety outcomes for codeine-based medications and NSAIDs among adults who underwent outpatient surgery through a systematic review and meta-analysis of randomized controlled trials (RCTs).

Managing postoperative pain in adult outpatients: a systematic review and meta-analysis comparing codeine with NSAIDs

Matthew Choi MD MPH, Li Wang PhD, Christopher J. Coroneos MD MSc, Sophocles H. Voinoskos MD MSc, James Paul MD MSc

Cite as: CMAJ 2021 June 14;193:E895-905. doi: 10.1503/cmaj.201915

ABSTRACT

BACKGROUND: Analgesics that contain codeine are commonly prescribed for postoperative pain, but it is unclear how they compare with nonopioid alternatives. We sought to compare the effectiveness of codeine and nonsteroidal anti-inflammatory drugs (NSAIDs) for adults who underwent outpatient surgery.

METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials comparing codeine and NSAIDs for postoperative pain in outpatient surgery. We searched MEDLINE and Embase from inception to October 2019 for eligible studies. Our primary outcome was the patient pain score, converted to a standard 10-point intensity scale. Our secondary outcomes were patient-reported global assessments and adverse effects. We used random-effects models and grading of recommendations assessment, development and evaluation (GRADE) to assess the quality of evidence.

RESULTS: Forty studies, including 102 trial arms and 5116 patients, met inclusion criteria. The studies had low risk of bias and low-to-moderate heterogeneity. Compared with codeine, NSAIDs were associated with better pain scores at 6 hours (weighted mean difference [WMD] 0.93 points, 95% confidence interval [CI] 0.71 to 1.15) and at 12 hours (WMD 0.79, 95% CI 0.38 to 1.19). Stronger NSAID superiority at 6 hours was observed among trials where acetaminophen was coadministered at equivalent doses between groups (WMD 1.18, 95% CI 0.87 to 1.48). NSAIDs were associated with better global assessments at 6 hours (WMD −0.88, 95% CI −1.04 to −0.72) and at 24 hours (WMD −0.67, 95% CI −0.95 to −0.40), and were associated with fewer adverse effects, including bleeding events.

INTERPRETATION: We found that adult outpatients report better pain scores, better global assessments and fewer adverse effects when their postoperative pain is treated with NSAIDs than with codeine. Clinicians across all specialties can use this information to improve both pain management and opioid stewardship.
Methods

We report this meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.17

Search strategy and study selection

With the assistance of a medical librarian, we systematically searched MEDLINE and Embase from inception to Oct. 28, 2019. Our search strategy is described in Appendix 1, eTables 1 and 2, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.201915/tab-related-content.

We included RCTs that compared oral codeine with oral NSAIDs prescribed to adult outpatients having acute postoperative pain. Our primary outcome of interest was efficacy, defined as the level of pain, measured by a validated pain scale. Secondary outcomes included patient-reported post-treatment global assessment score, and safety, measured by reported adverse effects. We included trials in which acetaminophen was coadministered with codeine or NSAIDs. We excluded trials in which intravenous drugs or drugs other than acetaminophen were coadministered. We also excluded trials that used medications that are no longer available because of safety concerns (e.g., zomepirac, indoprofen).

Using a standardized, pilot-tested form, 2 physicians screened titles and abstracts. The same physicians subsequently reviewed full texts of potentially eligible studies, independently and in duplicate, to assess for inclusion. They resolved disagreements with discussion.

Risk of bias assessment

We assessed individual studies’ risk of bias using the Cochrane risk of bias assessment tool, which includes assessment of random sequence generation, allocation concealment, blinding of participants and personnel, outcome assessment, incomplete outcome data, selective reporting and other sources of bias.18 Two authors assessed risk of bias, independently and in duplicate, and resolved disagreements by discussion. For the purposes of subgroup testing based on risk of bias, we dichotomized studies into high or low risk; we considered studies high risk if they had more than 1 bias category rated as high risk.

Data extraction

We developed and piloted a standardized, data extraction form. A single author extracted data, which was then verified independently by a second author. We collected study characteristics, patient characteristics, interventions and outcomes. Our primary outcome was pain, measured on a 10-point scale. If studies reported more than 1 pain score, we preferably used the patient-reported pain intensity score in the following order: 10-point scale, visual analogue scale, pain intensity difference score or sum of pain intensity difference. In the absence of these options, we used pain relief, mean peak pain relief or total pain relief, in that preferred order. We converted all pain measures to a 10-point scale to facilitate comparison.

We collected data on pain scores at 0 to 6 hours, 6 to 12 hours, 12 to 24 hours, 24 to 48 hours, 48 to 72 hours and more than 3 days after treatment. Our secondary outcomes were global assessments, on a 4-point scale, and adverse effects. We extracted all reported outcomes of adverse effects.

When multiarm trials included ineligible treatment arms, we extracted data only on the treatment arms meeting our eligibility criteria. When more than 1 arm within a single trial was eligible for inclusion (e.g., 1 codeine arm and 2 NSAID arms) we halved the “shared” group into 2 groups with halved sample size, then performed 2 direct comparisons, per Cochrane methodology.19 This method was chosen despite its limitations to allow separate trial arm comparisons for subgroup testing. We checked manuscripts by the same authorship for double-counting.

Statistical analysis

We calculated the Cohen κ statistic to evaluate interrater agreement. We converted all continuous outcome measures to a common reference scale, namely a 10-point scale of pain intensity (where lower is better) and a 4-point global assessment scale (where higher is better).20 If pain scores were reported using a scale where higher is better (opposite to the direction of the standard scale), then we inverted the data to maintain a consistent direction that lower is better. When the standard deviation (SD) of each group was not reported, we imputed the SD from the standard error, 95% confidence interval (CI), interquartile range, and p value; if these were not available, we imputed SDs from a similar study, per Cochrane methodology.19

We pooled all continuous outcomes using the weighted mean difference (WMD) and 95% CI, after conversion to the reference scale.20 This was to facilitate ease of clinical interpretation, so that a WMD of 1.0 would be equivalent to a 1-point difference on a 10-point scale for pain and a 1-point difference on a 4-point scale for global assessments. We set the minimal clinically important difference at 1.0 on a 10-point scale for pain, and 0.5 on a 4-point scale for global assessments.21,22 We pooled all binary outcomes using relative risks (RRs) and 95% CIs. We used a DerSimonian–Laird random effects model for all meta-analyses. We performed Grading of Recommendations Assessment, Development, and Evaluation (GRADE) quality and evidence assessments.

We used the Cochran χ² test, I² and the τ statistic to evaluate statistical heterogeneity. We conducted a priori subgroup analyses to evaluate the presence or absence of acetaminophen cointervention, type of NSAIDs (selective versus nonselective), surgery type and risk of bias. We predicted that acetaminophen would benefit both NSAID and codeine interventions, and we predicted that nonselective NSAIDs would be more effective than selective NSAIDs. If there were at least 10 studies available for meta-analysis, we assessed publication bias using funnel plots and the Egger test.21 We performed statistical analyses using Stata statistical software version (Version 15.1). All comparisons were 2-tailed using a threshold p ≤ 0.05.
Results

The results of our search strategy are summarized in Figure 1. We found a total of 1708 articles, and did not encounter any instances of double-counting. Screening, review and consensus ultimately resulted in 40 RCTs, 102 treatment arms (40 codeine treatment arms and 62 NSAID treatment arms), and 5116 patients (1872 patients prescribed codeine, and 3243 patients prescribed NSAIDs) being included for meta-analysis (Table 1 and Appendix 1, eTables 3 and 4). Various types and doses of NSAIDs were used. Codeine doses ranged from 15 mg to 90 mg, consistent with the most common outpatient formulations. The quality of studies included in the meta-analysis was high, with generally low risk of bias (Appendix 1, eFigures 1 and 2) and no evidence of publication bias (Appendix 1, eFigures 3, 4 and 5). The overall findings are summarized in the GRADE evidence profiles (Table 2 and Table 3).

Pain

Pain at ≤ 6 hours after treatment was reported for 4436 patients from 54 trial arm comparisons (Figure 2). High-quality evidence showed that patients who received NSAIDs had lower pain scores than those who received codeine, with a WMD of 0.93 points on a 10-point scale (95% CI 0.71 to 1.15, p = 0.009, I² = 33.9%). When comparing studies that either did not coadminister acetaminophen or used it with both NSAID and codeine groups, we found that patients using NSAIDs had even lower pain scores (WMD 1.18 points, 95% CI 0.87 to 1.48, test of interaction p = 0.05). NSAIDs had weaker superiority when acetaminophen was coadministered only with the codeine group (WMD 0.73 points, 95% CI 0.43 to 1.03). We did not detect any other subgroup effects (Appendix 1, eTable 5).

Pain at ≤ 12 hours after treatment was reported for 1660 patients from 19 trial arm comparisons (Figure 3). High-quality evidence showed that patients who received NSAIDs had lower pain scores than those who received codeine, with a WMD...
| Study                          | Surgery type | Codeine intervention                        | NSAID intervention                         | Maximum follow-up duration | Stated funding sources |
|-------------------------------|--------------|--------------------------------------------|--------------------------------------------|----------------------------|------------------------|
| Breivik et al., 1999<sup>14</sup> | Dental       | Acetaminophen/codeine 1000 mg/60 mg, n = 23 | Diclofenac/acetaminophen 100 mg/1000 mg, n = 24  
                              |               |                                            | Diclofenac 100 mg, n = 22          | 8 h                       | University             |
| Chang et al., 2001<sup>18</sup> | Dental       | Acetaminophen/codeine 600 mg/60 mg, n = 180 | Rofecoxib 50 mg, n = 182                     | 24 h                       | Industry               |
| Chen et al., 2009<sup>20</sup> | Plastic      | Acetaminophen/codeine 600 mg/60 mg, n = 17  | Ibuprofen 400 mg, n = 18                    | 4 d                        | None                   |
| Comfort et al., 2002<sup>27</sup> | Dental       | Acetaminophen/codeine 500 mg/8 mg, n = 80  | Diflusinal 250 mg, n = 66  
                              |               |                                            | Etodolac 200 mg, n = 80          | 24 h                       | None                   |
| Cooper et al., 1982<sup>28</sup> | Dental       | Codeine 60 mg, n = 41                       | Ibuprofen 400 mg, n = 38  
                              |               |                                            | ASA 650 mg, n = 38             | 4 h                        | Industry               |
| Cooper et al., 1988<sup>25</sup> | Dental       | Acetaminophen/codeine 600 mg/60 mg, n = 67  | Meclomenamate 100 mg, n = 36               | 6 h                        | Industry               |
| Cooper et al., 1991<sup>30</sup> | Dental       | Acetaminophen/codeine 650/60 mg, n = 39     | Flurbiprofen 50 mg, n = 42  
                              |               |                                            | Flurbiprofen 100 mg, n = 41     | 6 h                        | None                   |
| Cooper et al., 1993<sup>31</sup> | Dental       | Codeine 30 mg, n = 37                       | Ibuprofen 600 mg, n = 38  
                              |               |                                            | Ibuprofen 200 mg, n = 45       | 12 h                       | Industry               |
| Coutinho et al., 1976<sup>32</sup> | Urologic    | Codeine 30 mg, n = 14                       | Fenbufen 400 mg, n = 15  
                              |               |                                            | Fenbufen 800 mg, n = 16  
                              |                                            | ASA 600 mg, n = 15          | 5 h                        | Industry               |
| Daniels et al., 2011a<sup>33</sup> | Dental       | Acetaminophen/codeine 1000 mg/30 mg, n = 113| Ibuprofen/acetaminophen 200 mg/500 mg, n = 173  
                              |               |                                            | Ibuprofen/acetaminophen 400 mg/1000 mg, n = 168 | 12 h                       | Industry               |
| Daniels et al., 2011b<sup>34</sup> | Dental       | Acetaminophen/codeine 600 mg/60 mg, n = 62  | Ibuprofen 600 mg, n = 192  
                              |               |                                            | Ibuprofen 400 mg, n = 38  
                              |                                            | EIrirocixib 90 mg, n = 191  
                              |                                            | EIrirocixib 120 mg, n = 97 | 24 h                       | Industry               |
| De Los Santos et al., 1998<sup>26</sup> | General      | Acetaminophen/codeine 500 mg/30 mg, n = 67  | Lysine clonixinate 125 mg, n = 74           | 48 h                       | None                   |
| Desjardins et al., 1984<sup>36</sup> | Dental       | Codeine 60 mg, n = 40                       | ASA 650 mg, n = 40                           | 6 h                        | Industry               |
| Dionne et al., 1994<sup>27</sup> | Dental       | Acetaminophen/codeine 650/60 mg, n = 24     | Flurbiprofen 50 mg, n = 26  
                              |               |                                            | Flurbiprofen 100 mg, n = 22     | 6 h                        | Industry               |
| Forbes et al., 1982<sup>28</sup> | Dental       | Acetaminophen/codeine 600 mg/60 mg, n = 31  | Diflusinal 500 mg, n = 32  
                              |               |                                            | Diflusinal 1000 mg, n = 32       | 12 h                       | Industry               |
| Forbes et al., 1986<sup>39</sup> | Dental       | Codeine 60 mg, n = 44                       | Naproxen 550 mg, n = 38  
                              |               |                                            | ASA 650 mg, n = 36             | 12 h                       | Industry               |
| Forbes et al., 1989<sup>40</sup> | Dental       | Acetaminophen/codeine 600 mg/60 mg, n = 17  | Flurbiprofen 100 mg, n = 26               | 12 h                       | Industry               |
| Forbes et al., 1990a<sup>41</sup> | Dental       | Acetaminophen/codeine 600 mg/60 mg, n = 27  | Ketorolac 10 mg, n = 37  
                              |               |                                            | ASA 650 mg, n = 32             | 6 d                        | Industry               |
| Forbes et al., 1990b<sup>42</sup> | Dental       | Acetaminophen/codeine 600 mg/60 mg, n = 38  | Ketorolac 10 mg, n = 31  
                              |               |                                            | Ketorolac 20 mg, n = 35  
                              |                                            | Ibuprofen 400 mg, n = 34 | 6 d                        | Industry               |
| Gatouilis et al., 2012<sup>43</sup> | Dental       | Acetaminophen/codeine 300 mg/30 mg, n = 119 | ASA 1000 mg, n = 120                       | 7 d                        | Industry               |
| Giglio et al., 1990<sup>44</sup> | Dental       | Codeine 60 mg, n = 37                       | Meclofenamate 100 mg, n = 41               | 6 h                        | None                   |
| Giles et al., 1985<sup>45</sup> | Dental       | Codeine 60 mg, n = 29                       | Ibuprofen 400 mg, n = 37               | 3 d                        | Industry               |
| Giles et al., 1986<sup>46</sup> | Dental       | Codeine 15 mg, n = 42                       | Ibuprofen 200 mg, n = 37  
                              |               |                                            | ASA 600 mg, n = 39             | 7 d                        | None                   |
| Habib et al., 1990<sup>47</sup>  | Dental       | Acetaminophen/codeine/caffeine 500 mg/8 mg/30 mg, n = 25 | Ibuprofen 400 mg, n = 26  
                              |               |                                            | ASA/caffeine 300 mg/30 mg, n = 26 | 2 h                        | Industry               |
0.79 points on a 10-point scale (95% CI 0.38 to 1.19, \( p < 0.001, I^2 = 62.7\%\)). We did not find any subgroup effects. We found smaller differences between treatments at longer outcome horizons, with no subgroup effects.

**Secondary outcomes**

Global assessments showed statistically significant superiority of NSAIDs over codeine at all time measurements (Figure 4). Global assessment scores at ≤ 6 hours were available for 1452 patients and 21 trial arm comparisons. The WMD on a 4-point scale was –0.88 points at ≤ 6 hours (95% CI –1.04 to –0.72), –0.48 points at ≤ 12 hours (95% CI –0.78 to –0.19) and –0.67 points at ≤ 24 hours (95% CI –0.95 to –0.40). The minimal clinically important difference threshold of 0.5 was surpassed at 6 hours and 24 hours, according to high-quality evidence, indicating clinical importance. Between 2 and 7 days, the WMD was –0.32 points (95% CI –0.63 to –0.02), based on the smaller number of studies that reported this time horizon. Subgroup testing showed no interactions (Appendix 1, eTable 6).

Patients who received NSAIDs reported significantly fewer total adverse effects than those who received codeine. Moreover, fewer patients in the NSAID group reported nausea (10.4% v. 20.6%, WMD 10.2%, 95% CI 2.3% to 23.0%), vomiting (5.3% v. 18.8%, WMD 13.0%, 95% CI 2.7% to 36.6%), dizziness (3.4% v. 8.4%, WMD 5.0%, 95% CI 1.5% to 11.2%), drowsiness (5.6% v. 8.6%, WMD 3.0%, 95% CI –0.3% to 8.4%), and headache (4.5% v. 8.0%, WMD 3.5%, 95% CI

### Table 1 (part 2 of 2): Summary of included studies

| Study | Surgery type | Codeine intervention | NSAID intervention | Maximum follow-up duration | Stated funding sources |
|-------|--------------|----------------------|--------------------|-----------------------------|------------------------|
| Hersh et al., 1993 | Dental | Codeine 60 mg, \( n = 30 \) | Ibuprofen 400 mg, \( n = 24 \) | 6 h | Public |
| Indelicato et al., 1986 | Orthopedic | Acetaminophen/codeine 600 mg/60 mg, \( n = 9 \) | Diflunisal 500 mg, \( n = 11 \) | 5 d | None |
| Lysell et al., 1992 | Dental | Acetaminophen/codeine 500 mg/30 mg, \( n = 60 \) | Ibuprofen 600 mg, \( n = 60 \) | 6 d | None |
| Malmstrom et al., 2004 | Dental | Acetaminophen/codeine 600 mg/60 mg, \( n = 50 \) | Naproxen 550 mg, \( n = 51 \), Etoricoxib 120 mg, \( n = 50 \) | 10 d | Industry |
| Malmstrom et al., 2005 | Dental | Acetaminophen/codeine 600 mg/60 mg, \( n = 50 \) | Etoricoxib 120 mg, \( n = 100 \) | 24 h | Industry |
| Mehlisch et al., 1984 | Dental | Codeine 90 mg, \( n = 27 \) | Ketoprofen 25 mg, \( n = 24 \), Ketoprofen 50 mg, \( n = 27 \), Ketoprofen 100 mg, \( n = 27 \) | 6 h | Industry |
| Mitchell et al., 2008 | General | Acetaminophen/codeine/caffeine 300 mg/30 mg/15 mg, \( n = 71 \) | Ibuprofen/acetaminophen 400 mg/325 mg, \( n = 69 \) | 7 d | Public and unrestricted industry grant |
| Mitchell et al., 2012 | Plastic | Acetaminophen/codeine/caffeine 600 mg/60 mg/30 mg, \( n = 70 \) | Ibuprofen/acetaminophen 400 mg/650 mg, \( n = 71 \) | 7 d | Public |
| Ottinger et al., 1990 | Orthopedic | Acetaminophen/codeine 300 mg/30 mg, \( n = 42 \) | Flurbiprofen 50 mg, \( n = 41 \) | 4 d | Industry |
| Raeder et al., 2001 | General | Acetaminophen/codeine 800 mg/60 mg, \( n = 53 \) | Ibuprofen 800 mg, \( n = 51 \) | 3 d | Industry |
| Scoren et al., 1987 | Dental | Acetaminophen/codeine 300 mg/30 mg, \( n = 30 \) | Naproxen 275 mg, \( n = 47 \) | 7 d | Industry |
| Sniezek et al., 2011 | Otolaryngology | Acetaminophen/codeine 325 mg/30 mg, \( n = 70 \) | Ibuprofen/acetaminophen 400 mg/1000 mg, \( n = 68 \) | 12 h | None |
| Soulier et al., 1997 | Orthopedic | Acetaminophen/codeine 300 mg/30 mg, \( n = 24 \) | Flurbiprofen 50 mg, \( n = 29 \) | 4 d | Industry |
| Sunshine et al., 1986 | Dental | Acetaminophen/codeine 650 mg/60 mg, \( n = 31 \) | Flurbiprofen 50 mg, \( n = 31 \), Flurbiprofen 100 mg, \( n = 29 \) | 6 h | Industry |
| Vargas Busquets et al., 1998 | Plastic | Acetaminophen/codeine 600 mg/60 mg, \( n = 48 \) | Naproxen 550 mg, \( n = 43 \) | 6 h | None |
| Wittenberg et al., 1984 | Orthopedic | Acetaminophen/codeine 300 mg/30 mg, \( n = 31 \) | Ibuprofen 400 mg, \( n = 34 \) | 4 h | Industry |

Note: ASA = acetylsalicylic acid, NSAID = nonsteroidal anti-inflammatory drug.
### Table 2: GRADE evidence profile for pain and global assessment scores, codeine compared with NSAIDs

| No. of trials* | No. of patients | Outcome time horizon | Serious risk of bias† | Serious inconsistency \((P, \tau)\) | Serious indirectness | Serious imprecision | Publication bias detected‡ | Treatment effect, points, WMD (95% CI) | Overall quality |
|----------------|----------------|----------------------|-----------------------|-----------------------------|----------------------|-----------------------|-------------------------------|----------------------------------|----------------|
| **Pain**       |                |                      |                       |                             |                      |                       |                               |                                  |                |
| 31 (54 comparisons) | 4436           | ≤ 6 h                | No                    | No (33.9%, 0.43)           | No                   | No                    | No (symmetric, \(p = 0.57\)) | 0.93 (0.71 to 1.15)              | High           |
| 10 (19 comparisons) | 1660           | ≤ 12 h               | No                    | No (62.7%, 0.68)          | No                   | No                    | No (symmetric, \(p = 0.31\)) | 0.79 (0.38 to 1.19)              | High           |
| 8 (9 comparisons) | 888            | ≤ 24 h               | No                    | No (20.8%, 0.25)          | No                   | No                    | No                            | 0.16 (–0.20 to 0.52)             | High           |
| 6              | 552            | ≤ 48 h               | No                    | Yes (88.7%, 1.42)         | No                   | Yes**                 | No                            | 0.60 (–0.74 to 1.93)             | Low            |
| 6              | 485            | ≤ 72 h               | No                    | No (0%, 0.00)             | No                   | No                    | No                            | 0.07 (–0.26 to 0.39)             | High           |
| 5              | 305            | 4 to 7 d             | No                    | No (54.8%, 0.52)          | No                   | No                    | No                            | 0.03 (–0.59 to 0.65)             | High           |
| **Global assessment**       |                |                      |                       |                             |                      |                       |                               |                                  |                |
| 12 (21 comparisons) | 1452           | ≤ 6 h                | No                    | No (0%, 0.00)             | No                   | No                    | No (symmetric, \(p = 0.69\)) | –0.88 (–1.04 to –0.72)            | High           |
| 7 (13 comparisons) | 1043           | ≤ 12 h               | No                    | No (54.2%, 0.38)          | No                   | Yes**                 | No (symmetric, \(p = 0.02\)) | –0.48 (–0.78 to –0.19)            | Moderate        |
| 4 (7 comparisons) | 947            | ≤ 24 h               | No                    | No (60.7%, 0.29)          | No                   | No                    | No                            | –0.67 (–0.95 to –0.40)            | High           |
| 4 (5 comparisons) | 343            | 2 to 7 d             | No                    | No (12.2%, 0.13)          | No                   | No                    | No                            | –0.32 (–0.63 to –0.02)            | High           |

Note: CI = confidence interval, GRADE = Grading of recommendations, assessment, development and evaluations, NSAIDs = nonsteroidal anti-inflammatory drugs, WMD = weighted mean difference.

*We used comparison-level data for multiarm trials.

†Publication bias detected using funnel plots if there were at least 10 studies available for meta-analysis. The Egger test measures the symmetry of funnel plots.

‡We did not rate down for risk of bias, as we did not detect any significant difference between low and high risk of bias.

§Pain was measured on a 10-point scale (positive WMD favours NSAIDs) and global assessments were measured on a 4-point scale (negative WMD favours NSAIDs).

*We did not rate down for imprecision, as the 95% CI is still narrow (i.e., the clinical decisions will not change based on the boundaries of 95% CI), although the 95% CI crosses null effect line.

**We rated down for serious imprecision, as the 95% CI includes both benefit and harm, and the clinical decisions will change based on the boundaries of 95% CI.

### Table 3: GRADE evidence profile for adverse effect outcomes, codeine compared with NSAIDs

| No. of trials* | No. of patients | Outcome time horizon | Serious risk of bias† | Serious inconsistency \((P, \tau)\) | Serious indirectness | Serious imprecision | Publication bias detected‡ | RR (95% CI) | Overall quality |
|----------------|----------------|----------------------|-----------------------|-----------------------------|----------------------|-----------------------|----------------------------|--------------|----------------|
| **Nausea**     |                |                      |                       |                             |                      |                       |                               |              |                |
| 27             | 3780           | 2 h to 8 d           | No†                   | Yes (80.7%, 0.90)          | No                   | No                    | No (symmetric, \(p = 0.05\)) | 1.98 (1.22 to 3.20)              | Moderate      |
| **Vomiting**   |                |                      |                       |                             |                      |                       |                               |              |                |
| 11             | 2282           | 5 h to 8 d           | No†                   | Yes (76.2%, 0.97)          | No                   | No                    | No (symmetric, \(p = 0.14\)) | 3.45 (1.51 to 7.90)              | Moderate      |
| **Dizziness**  |                |                      |                       |                             |                      |                       |                               |              |                |
| 17             | 2896           | 4 h to 8 d           | No†                   | No (44.5%, 0.68)          | No                   | No                    | No (symmetric, \(p = 0.54\)) | 2.49 (1.43 to 4.33)              | High          |
| **Drowsiness** |                |                      |                       |                             |                      |                       |                               |              |                |
| 15             | 2052           | 2 h to 8 d           | No†                   | No (40.4%, 0.56)          | No                   | Yes§                  | No (symmetric, \(p = 0.20\)) | 1.53 (0.94 to 2.49)              | Moderate      |
| **Headache**   |                |                      |                       |                             |                      |                       |                               |              |                |
| 23             | 3547           | 2 h to 8 d           | No†                   | No (0%, 0.00)             | No                   | No                    | No (symmetric, \(p = 0.18\)) | 1.77 (1.32 to 2.36)              | High          |
| **Bleeding/hematoma** |        |                      |                       |                             |                      |                       |                               |              |                |
| 8              | 895            | 12 h to 7 d          | No                    | No (0%, 0.00)             | No                   | Yes§                 | No (symmetric, \(p = 0.08\)) | 1.66 (0.50 to 1.20)              | Moderate      |
| **Any adverse effect** |      |                      |                       |                             |                      |                       |                               |              |                |
| 23             | 3246           | 2 h to 8 d           | No†                   | No (35.5%, 0.17)          | No                   | No                    | No (symmetric, \(p = 0.08\)) | 1.47 (1.28 to 1.68)              | High          |

Note: CI = confidence interval, GRADE = Grading of recommendations, assessment, development and evaluations, NSAIDs: nonsteroidal anti-inflammatory drugs, RR = Relative risk

*We used comparison-level data for multiarm trials.

†Publication bias detected using funnel plots if there were at least 10 studies available for meta-analysis. The Egger test measures the symmetry of funnel plots.

‡We did not rate down for risk of bias, as we did not detect any significant difference between low versus high risk of bias.

§We did not rate down for imprecision, as we did not detect any significant difference between low versus high risk of bias.

§§We rated down for serious imprecision as the 95% CI includes both benefit and harm; and the clinical decisions will change based on the boundaries of 95% CI.
1.5% to 6.2%). Fewer patients in the NSAID groups reported any adverse effect than in the codeine group (28.9% vs. 42.4%, WMD 13.6%, 95% CI 8.1% to 19.6%). Eight trials (895 patients) specifically reported bleeding or hematoma as a separate outcome measure. These bleeding events were less frequent in the NSAID arms, but no statistically significant difference was observed in the event rate between the 2 treatments (0.9% vs. 1.5%, WMD 0.6%, 95% CI –0.4% to 4.0%).

**Interpretation**

We found high-quality evidence that outpatient postoperative adults taking NSAIDs reported less pain at 6 and 12 hours than those taking codeine in a meta-analysis of RCTs. The mean effect size for this superiority was below the minimal clinically important difference threshold of 1.0; however, the 95% CI included the threshold and did not include zero. This showed that many patients experience a clinically important benefit with NSAIDs over codeine. Furthermore, the risk of an inferior clinical effect from NSAIDs was statistically negligible.64,65

We also observed that when NSAIDs and codeine were coadministered with equivalent doses of acetaminophen, NSAID superiority was above the threshold for a minimal clinically important difference. This shows that, with or without acetaminophen coadministration, NSAIDs delivered a clinically superior analgesic coadministered with equivalent doses of acetaminophen, NSAID superiority was above the threshold for a minimal clinically important difference. This shows that, with or without acetaminophen coadministration, NSAIDs delivered a clinically superior analgesic.

---

**Figure 2:** Forest plots of the weighted mean differences (WMD) and 95% confidence intervals (CIs) of pain scores at ≤ 6 hours among postoperative patients who were prescribed codeine or nonsteroidal anti-inflammatory drugs (NSAIDs). Note: SD = standard deviation.
Evidence to the contrary. We found more bleeding or hematoma use of NSAIDs in a postoperative setting is the potential of the most commonly reported adverse effects (i.e., nausea, codeine, with significantly lower rates of any adverse effects, and evidence of fewer adverse effects from NSAIDs than from patients’ experiences of analgesia efficacy, tolerability and a composite patient-reported outcome that incorporates 6 hours, 0.5 points at 12 hours and 0.7 points at 24 hours. Global magnitude of difference on a 4-point scale was about 1 point at statistically and clinically superior to codeine at all time points. The at- to high-quality GRADE evidence that NSAIDs were statisti- cally and clinically superior to codeine at all time points. The lack of significant interaction effects contradicting our main results.

We evaluated patient global assessments and found moderate- to high-quality GRADE evidence that NSAIDs were statistically and clinically superior to codeine at all time points. The magnitude of difference on a 4-point scale was about 1 point at 6 hours, 0.5 points at 12 hours and 0.7 points at 24 hours. Global assessments of pain intervention can be interpreted clinically as a composite patient-reported outcome that incorporates patients’ experiences of analgesia efficacy, tolerability and adverse effects. We also found moderate- to high-quality GRADE evidence of fewer adverse effects from NSAIDs than from codeine, with significantly lower rates of any adverse effects, and of the most commonly reported adverse effects (i.e., nausea, vomiting, dizziness, headache). One common hesitation with the use of NSAIDs in a postoperative setting is the potential increased risk of bleeding, but we found moderate-quality evidence to the contrary. We found more bleeding or hematoma events with codeine treatment, although the event rates between the 2 treatments were not statistically different.

Codeine remains the most commonly prescribed opioid in Canada, despite its many shortcomings.6–9,66 Codeine is a prodrug that requires metabolism to morphine by the CYP2D6 enzyme for analgesic effect. Overall, about 10% of ingested codeine is metabolized to morphine; however, there is substantial individual-level variability in CYP2D6 enzyme expression, ranging from nonmetabolizing people without any morphine conversion to ultra-rapid metabolizers with extremely high morphine conversion.57–69 Consequently, routine codeine dosages can result in a spectrum of effects ranging from no analgesia to life-threatening levels of circulating morphine. These unique pharmacogenetic features have raised a number of safety concerns, particularly with respiratory depression.69,70 This is in addition to codeine’s many common adverse effects, including nausea, vomiting, constipation, urinary retention and sedation, all of which reduce compliance and increase rescue medication usage.71 Our findings are consistent with codeine’s known disadvantages. We sus- pect that the anti-inflammatory mechanism of action of NSAIDs are better suited to the acute pain of postoperative patients.16

These findings are of general importance to any clinician per- forming painful medical procedures. The various trials in our meta-analysis evaluated a range of procedures, different NSAID types and various degrees of acetaminophen coadministration.

| Study                  | WMD (95% CI) | Codeine n | Codeine Mean ± SD | NSAIDs n | NSAIDs Mean ± SD |
|-----------------------|-------------|-----------|-------------------|----------|-----------------|
| Breivik et al., 1999a | 0.60 (–0.68 to 1.88) | 12 | 2.50 ± 1.84 | 24 | 1.90 ± 1.87 |
| Breivik et al., 1999a | –1.30 (–2.62 to 0.02) | 11 | 2.50 ± 1.84 | 22 | 3.80 ± 1.79 |
| Comfort et al., 2002a | 1.40 (0.16 to 2.64) | 40 | 4.00 ± 3.23 | 66 | 2.60 ± 3.06 |
| Comfort et al., 2002a | –0.13 (–0.92 to 0.66) | 40 | 3.00 ± 1.73 | 80 | 3.13 ± 2.68 |
| Comfort et al., 2002a | 0.75 (–0.01 to 1.51) | 40 | 3.00 ± 1.73 | 66 | 2.25 ± 2.20 |
| Comfort et al., 2002a | 0.45 (–0.73 to 1.63) | 40 | 4.00 ± 3.23 | 80 | 3.55 ± 2.89 |
| Cooper et al., 1993a | 1.18 (–0.56 to 2.93) | 18 | –2.66 ± 3.24 | 38 | –3.84 ± 2.83 |
| Cooper et al., 1993a | 1.21 (–0.45 to 2.87) | 19 | –2.66 ± 3.24 | 45 | –3.87 ± 2.74 |
| Daniels et al., 2011a | –0.17 (–0.86 to 0.53) | 57 | –2.50 ± 2.34 | 173 | –2.33 ± 2.24 |
| Daniels et al., 2011a | 2.00 (1.29 to 2.71) | 56 | –2.50 ± 2.34 | 168 | –4.50 ± 2.41 |
| Forbes et al., 1982a | 1.27 (–0.24 to 2.79) | 15 | –2.28 ± 2.47 | 32 | –3.55 ± 2.47 |
| Forbes et al., 1982a | 1.90 (0.20 to 3.60) | 16 | –2.28 ± 2.84 | 32 | –4.18 ± 2.84 |
| Forbes et al., 1986a | –0.19 (–1.15 to 0.78) | 22 | –1.11 ± 1.82 | 36 | –0.92 ± 1.82 |
| Forbes et al., 1986a | 1.93 (0.63 to 3.23) | 22 | –1.11 ± 1.82 | 38 | –3.04 ± 3.30 |
| Forbes et al., 1989a | 0.96 (–0.33 to 2.25) | 17 | –1.63 ± 1.79 | 26 | –2.60 ± 2.53 |
| Indelicato et al., 1986a | 1.27 (–0.83 to 3.36) | 9 | 3.67 ± 2.47 | 11 | 2.40 ± 2.25 |
| Malmstrom et al., 2004a | 1.50 (0.49 to 2.51) | 25 | –3.50 ± 2.25 | 51 | –5.00 ± 1.82 |
| Malmstrom et al., 2004a | 1.25 (0.23 to 2.27) | 25 | –3.50 ± 2.25 | 50 | –4.75 ± 1.80 |
| Snieszek et al., 2011a | 0.36 (–0.22 to 0.94) | 70 | 0.97 ± 1.83 | 68 | 0.61 ± 1.66 |
| Overall (I² = 62.7%, p < 0.000) | 0.79 (0.38 to 1.19) | 554 | 1106 |

Figure 3: Forest plots of the weighted mean differences (WMD) and 95% confidence intervals (CIs) of pain scores at ≤ 12 hours among postoperative patients who were prescribed codeine or nonsteroidal anti-inflammatory drugs (NSAIDs). Note: SD = standard deviation.
do not apply. The overall results may not generalize to all types of patients. Many of the trials analyzed came from the dental literature; however, our findings remained consistent when excluding dental studies from analysis (data not shown).

Conclusion

In our meta-analysis of RCTs, we found that patients randomized to NSAIDs following outpatient surgical procedures reported better pain scores, better global assessment scores, fewer adverse effects and no difference in bleeding events, compared with those receiving codeine. These findings strengthen existing evidence and are broadly generalizable to patients across surgical disciplines. Further studies should assess the comparative effectiveness of other nonopioid analgesics, and test these findings in other populations and settings.

The low-to-moderate heterogeneity, combined with the consistent statistically significant findings, allows for generalizable results with broad clinical application. In all surgery types, subgroups and outcome time points, NSAIDs were equal or superior to codeine for postoperative pain, with higher global assessments and fewer adverse effects.

Limitations

We found low-to-moderate heterogeneity in our analysis because of the variety of interventions and dosages. However, NSAIDs showed consistent equivalence or superiority, but there may be some dosages of codeine or NSAID for which our findings do not apply. The overall results may not generalize to all types of patients.
17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PloS One* 2009;4:e6690.

18. Higgins J, Green S, editors. *Cochrane handbook for systematic reviews of interventions*. Version 5.1.0. [updated March 2011]. Oxford (UK): The Cochrane Collaboration; 2011.

19. Thorlund K, Walter SD, Johnston BC, et al. Pooling health-related quality of life outcomes in meta-analysis—a tutorial and review of methods for enhancing interpretability. *Res Synth Methods* 2011;2:188-203.

20. Salaffi F, Stancati A, Silvestri CA, et al. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. *Eur J Pain* 2004;8:283-91.

21. Todd KH, Funk KG, Funk JP, et al. Clinical significance of reported changes in pain severity. *Ann Emerg Med* 1996;27:485-9.

22. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629-34.

23. Breivik EK, Barkvoll P, Skovlund E. Combining diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: a randomized, double-blind single-dose study. *Clin Pharmacol Ther* 1999;66:625-35.

24. Chang DJ, Fricke JR, Bird SR, et al. Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial. *Clin Ther* 2001;23:1446-55.

25. Chen T, Adamson PA. Comparison of ibuprofen and acetaminophen with codeine following cosmetic facial surgery. *J Otolaryngol Head Neck Surg* 2009;38:580-6.

26. Comfort MB, Tse AS, Tsang AC, et al. A study of the comparative efficacy of three common analgesics in the control of pain after third molar surgery under local anesthesia. *Aust Dent J* 2002;47:327-30.

27. Cooper SA, Engel J, Ladov M, et al. Analgesic efficacy of an ibuprofen-codeine combination. *Pharmacotherapy* 1982;2:162-7.

28. Cooper SA, Firestein A, Cohn P. Double-blind comparison of meclofenamate sodium with acetaminophen, acetaminophen with codeine and placebo for relief of postsurgical dental pain. *J Clin Dent* 1988;1:31-4.

29. Cooper SA, Kupperman A. The analgesic efficacy of flurbiprofen compared to acetaminophen with codeine. *J Clin Dent* 1991;2:70-4.

30. Cooper SA, Quinn PD, MacAfee K, et al. Ibuprofen controlled-release formulation: A clinical trial in dental impaction pain. *Oral Surg Oral Med Oral Pathol* 1993;75:677-83.

31. Coutinho A, Bonelli J, de Carvalho PC. A double-blind comparative study of the analgesic effects of fenbufen, codeine, aspirin, propoxyphene and placebo. *Curr Ther Res Clin Exp* 1976;19:58-65.

32. Daniels SE, Goulder MA, Aspley S, et al. A randomised, five parallel-group, placebo-controlled trial comparing the efficacy and tolerability of analgesic combinations including a novel single-tablet combination of ibuprofen/paracetamol for postoperative dental pain. *Pain* 2011;152:632-42.

33. Daniels SE, Bandy DP, Christensen SE, et al. Evaluation of the dose range of etoricoxib in an acute pain setting using the postoperative dental pain model. *Clin J Pain* 2011;27:1-8.

34. de los Santos AR, Di Girolamo G, Marti ML. Efficacy and tolerance of lynine cloxinate versus paracetamol/codeine following inguinal hernioplasty. *Int J Tissue React* 1996;20:71-81.

35. Desjardins PJ, Cooper SA, Gallegos TL, et al. The relative analgesic efficacy of propiram fumarate, codeine, aspirin, and placebo in post-impaction dental pain. *J Clin Pharmacol* 1984;24:35-42.

36. Dionne RA, Snyder J, Hargreaves KM. Analgesic efficacy of flurbiprofen in comparison with acetaminophen, acetaminophen codeine plus placebo and placebo after impacted third molar removal. *J Oral Maxillofac Surg* 1994:52:919-24, discussion 25-6.

37. Forbes JA, Beaver WT, White EH, et al. Diflunisal. A new oral analgesic with an unusually long duration of action. *JAMA* 1982;246:2139-42.

38. Forbes JA, Keller CK, Smith JW, et al. Analgesic effect of naproxen sodium, codeine, a naproxen-codeine combination and aspirin on the postoperative pain of oral surgery. *Pharmacotherapy* 1986;6:211-8.

39. Forbes JA, Butterworth GA, Burchfield WH, et al. Evaluation of flurbiprofen, acetaminophen, an acetaminophen-codeine combination, and placebo in postoperative oral surgery pain. *Pharmacotherapy* 1989;9:322-30.

40. Forbes JA, Butterworth GA, Burchfield WH, et al. Evaluation of ketorolac, aspirin, and an acetaminophen-codeine combination in postoperative oral surgical pain. *Pharmacotherapy* 1990;10:775-935.

41. Forbes JA, Kehm CJ, Grodin CD, et al. Evaluation of ketorolac, ibuprofen, acetaminophen, and an acetaminophen-codeine combination in postoperative oral surgical pain. *Pharmacotherapy* 1990;10:945-1055.

42. Gatoulis SC, Voelker M, Fisher M. Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension-type headache and postoperative dental pain. *Clin Ther* 2012;34:138-48.

43. Giglio JA, Laskin DM. Double-blind comparison of meclofenamate sodium plus codeine, meclofenamate sodium, codeine, and placebo for relief of pain following surgical removal of third molars. *J Oral Maxillofac Surg* 1990;48:785-90.

44. Giles AD, Pickvance N. Combination analgesia following oral surgery: a double-blind comparison of ibuprofen, codeine phosphate and two combination ratios. *Clin Trials* 1985;2:22-300-11.

45. Giles AD, Hill CM, Shepherd JP, et al. A single dose assessment of an ibuprofen/codeine combination in postoperative dental pain. *Int J Oral Maxillofac Surg* 1986;15:727-32.

46. Habib S, Matthews RW, Scully C, et al. A study of the comparative efficacy of four common analgesics in the control of postsurgical dental pain. *Oral Surg Oral Med Oral Pathol* 1990;70:559-63.

47. Hersh EV, Ochs H, Quinn P, et al. Narcotic receptor blockade and its effect on the analgesic response to placebo and ibuprofen after oral surgery. *Oral Surg Oral Med Oral Pathol* 1993;75:539-46.

48. Indelicato PA. Efficacy of diflunisal versus acetaminophen with codeine in controlling mild to moderate pain after arthroscopy. *Clin Ther* 1986;8:164-9.
